Fortis Healhcare

No plans to list diagnostic arm Agilus Diagnostics: IHH Healthcare

Engaging with regulator on open offer for 26.1% stake in Fortis

Fortis Health hits 52-week high on plans to buy 32% stake in subsidiary

Fortis Healthcare's stock price today surged after the healthcare company said that it will buy the entire 31.52 per cent stake held by private equity investors in the material wholly owned subsidiary

Fortis Healthcare to acquire 31% stake in Agilus for Rs 1,780 crore

Deal values diagnostic arm at Rs 5,700 crore

Fortis Healthcare Q1 results: Profit rises 40% over hospital biz growth

The company's revenue from operations rose to Rs 1,859 crore in Q1FY25, a 12.2 per cent Y-o-Y rise from Rs 1,657 crore reported in Q1FY24

PE firm Blackstone likely to own majority in Aster-Care merged entity

While the unlisted Quality Care India is valued at around Rs 16,826 crore ($2 billion) by bankers, Aster DM Healthcare's total market valuation was Rs 18,424 crore as of Monday

Nomura ups target price for Fortis, sees 12% upside; reiterates 'Buy'

The global brokerage firm maintained its 'Buy' call for Fortis Healthcare with an updated twelve month forward target price of Rs 547, a 12 per cent upside to Monday's close

IndiGo, HCLTech, JK Lakshmi Cement among nine stocks to track on May 24

On Thursday, US markets closed in the red as robust economic data dashed hopes for Federal Reserve rate cuts

Q4 results today: IndiGo, ITC, and Fortis among 181 firms to post earnings

Company Q4 FY24 results today: ICRA, Rupa & Company, Page Industries, and Shilpa Medicare will also release their fourth quarter earnings report on May 23

Stocks to Buy: Here's why Angel One is bullish on Fortis, Piramal Pharma

Stocks picks by Angel One: Fortis Healthcare is in a secular uptrend, hovering above its EMAs (Exponential Moving Average) on the daily time frame chart

Fortis Healthcare Q3 results: Profit down 3.2%, revenue grows by 7.7%

The company reported a fall in bed occupancy to 64 per cent in Q3FY24, from 66.1 per cent in the same quarter last year. This has been attributed to the addition of 100 operation beds

Fortis Healthcare plans acquisitions, may opt for neutral brand name

We have taken a calculative view that at least for SRL, we have moved to the Agilus brand, and we have successfully completed that last year, said CFO of Fortis Healthcare

Fortis launches institute for specialised treatment of blood cancer

A well-known private healthcare group, Fortis on Friday inaugurated a state-of-the-art facility for the specialised treatment of blood cancers and disorders, which it said "represented a critical step" in addressing the urgent need for comprehensive holistic care. The Fortis Institute of Blood Disorders also integrates paediatric and geriatric care, advanced transplant procedures, and hematopathology expertise, all under one roof, Fortis Healthcare said in a release. The Institute also launched CAR-T cell therapy to its extensive network of Bone Marrow Transplant centres in Mohali, Delhi, Gurgaon, Noida, Mumbai and Bangalore, the statement said. This initiative is supported by a commercial collaboration with ImmunoACT, an IIT-Bombay spin-off and pioneer in India's first fully indigenous and commercially approved gene-modified cell therapy. The NexCAR19, India's first market-authorised CAR-T cell therapy, offers a new ray of hope for treating B-cell lymphomas and B-acute lymphoblast

As Covid-19 cases rise in India; should you keep pharma stocks on radar?

Barring Dr Lal Pathlabs, the other four healthcare related stocks listed below seem to be trapped in a range for now, charts suggest.

Hospitals see 7-8% surge in patient footfall, new investments in 2023

Jose told Business Standard that investments in medical equipment and increasing bed capacities have picked up in 2023 after a hiatus during the Covid19 period

Fortis Healthcare Q2 results: Net profit declines 15% to Rs 173.7 crore

The company declared results post-market hours. Fortis Healthcare Limited stock was up by 17 basis points (5 per cent) on the BSE to Rs 359.15 apiece

Manipal Hospitals to add 750 beds in WB, Odisha under east expansion plan

Nationally, Manipal Hospitals boasts a capacity of 9,500 beds

Fortis Healthcare PAT falls 8.6% to Rs 122.5 cr in April-June quarter

Fortis Healthcare Ltd on Friday reported an 8.6 per cent decline in consolidated profit after tax to Rs 122.5 crore for the first quarter ended June 30. The company, which posted a consolidated profit after tax of Rs 134.3 crore in the first quarter of the last fiscal, said its diagnostics business has been renamed as Agilus Diagnostics Ltd, and the boards of the two firms have granted approval for the latter to initiate an initial public offer (IPO) process. Its consolidated revenues in the first quarter stood at Rs 1,657 crore against Rs 1,488 crore in the year-ago period, a growth of 11.4 per cent. "We have witnessed a steady start in Q1 FY24 for both the hospitals and diagnostics business. Our hospital business revenues grew 13.6 per cent to Rs 1,354 crore while operating EBITDA was at Rs 206.4 crore, reflecting a margin of 15.2 per cent versus 16.2 per cent in Q1 FY23. "This was in part due to a lower occupancy and a comparatively less favourable payor mix, both of which we ..

Coal India inks MoU with Fortis Healthcare to treat thalassemic children

Fortis Healthcare has joined hands with Coal India to treat underprivileged children suffering from thalassemia under the 'Thalassemia Bal Sewa Yojana' CSR initiative of the central public sector enterprise. An MoU in this connection was signed on July 28 at the Fortis Memorial Research Institute in Gurugram, a hospital statement said. Coal India launched the 'Thalassemia Bal Sewa Yojana' in 2017 to support the treatment of underprivileged children affected by thalassemia. In 2020, aplastic anaemia was added to the programme. According to the MoU, Coal India will provide financial assistance of up to Rs 10 lakh to eligible patients for bone marrow transplants and the treatment can be done at Fortis Memorial Research Institute. The health centre has one of the largest and most comprehensive bone marrow transplant centres in India that boasts a team of nearly 20 doctors with expertise in the treatment of all kinds of blood disorders. The Bone Marrow Transplant Centre at the hospital

CRISIL upgrades credit rating of Fortis Healthcare in biz risk profile

Crisil has upgraded the credit rating outlook of Fortis Healthcare basis sustained improvement in the business risk profile of the company. It has upgraded the credit rating on long-term bank facilities for Fortis Healthcare Limited (FHL) to 'AA / Stable outlook' from the earlier 'AA- / Positive outlook', the company said in a release. The short- term rating has also been reaffirmed at 'Crisil A1+'. This rating is considered to have a high degree of safety regarding timely payment of financial obligations. "Crisil upgraded long-term credit rating to AA basis sustained improvement in the business risk profile of FHL driven by bed expansions, steady occupancies, better surgical mix, improved average revenue per occupied bed (ARPOB) metrics, and increasing international patient revenues, which are also leading to healthy operating profitability," it said. It further said consolidated operating EBITDA of FHL improved to about Rs 1,163 crore in 2022-23 from Rs 1,096 crore in FY22 and ne

Sebi issues demand notices to 5 entities in Fortis fund diversion case

Capital markets regulator Sebi has sent notices to five entities asking them to pay Rs 5.7 crore within 15 days in Fortis Healthcare's case of fund diversion and misrepresentations to conceal the fraud. In addition, the regulator warned of attachment of assets and accounts if they fail to make the payment within the stipulated time. The five entities that received notices are Saubhagya Buildcon, Zolton Properties, Tiger Developers, Torus Buildcon and Rosestar Marketing. The demand notices came after the entities failed to pay the fine imposed on them by the Securities and Exchange Board of India (SEBI) in May 2020. In five notices issued on Thursday, Sebi directed them to pay Rs 5.7 crore, which includes interest and recovery cost, within 15 days. In the event of non-payment of dues, the regulator will recover the amount by attaching and selling their moveable and immovable properties. Besides, they will face attachment of their bank accounts. Also, the regulator takes the route o